TJ294B - Method for selective methionine starvation of malignant cells in mammals - Google Patents
Method for selective methionine starvation of malignant cells in mammalsInfo
- Publication number
- TJ294B TJ294B TJ96000320A TJ96000320A TJ294B TJ 294 B TJ294 B TJ 294B TJ 96000320 A TJ96000320 A TJ 96000320A TJ 96000320 A TJ96000320 A TJ 96000320A TJ 294 B TJ294 B TJ 294B
- Authority
- TJ
- Tajikistan
- Prior art keywords
- malignant cells
- mammal
- mtase
- mammals
- methionine
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 title abstract 3
- 230000003211 malignant effect Effects 0.000 title abstract 3
- 229930182817 methionine Natural products 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 235000003642 hunger Nutrition 0.000 title 1
- 230000037351 starvation Effects 0.000 title 1
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 abstract 5
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 abstract 5
- 238000001514 detection method Methods 0.000 abstract 2
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 abstract 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
An improved method for chemotherapy of mammalian malignant cells which have an absolute requirement for methionine but lack methylthioadenosine phosphorylase (MTAse). The method comprises detection of MTAse negative cells in a mammal, administration of methionine gamma -lyase in sufficient amounts to reduce the volume of MTAse negative cells in the mammal, and co-administration of methylthioadenosine in amounts sufficient to ensure the continued availability of methionine to the mammal's non-malignant cells. Means for detection of MTAse negative cells are provided. Means for production and use of recombinant chemotherapeutic agents are also provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/176,413 US5571510A (en) | 1993-12-29 | 1993-12-29 | Method for selective methionine starvation of malignant cells in mammals |
| PCT/US1994/014919 WO1995017908A1 (en) | 1993-12-29 | 1994-12-22 | Method for selective methionine starvation of malignant cells in mammals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TJ294B true TJ294B (en) | 2001-03-30 |
Family
ID=22644262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TJ96000320A TJ294B (en) | 1993-12-29 | 1994-12-22 | Method for selective methionine starvation of malignant cells in mammals |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5571510A (en) |
| EP (1) | EP0805690B1 (en) |
| JP (1) | JPH09507754A (en) |
| CN (1) | CN1143325A (en) |
| AT (1) | ATE221785T1 (en) |
| AU (1) | AU694161B2 (en) |
| CA (1) | CA2180262A1 (en) |
| CZ (1) | CZ291281B6 (en) |
| DE (1) | DE69431167T2 (en) |
| HU (1) | HU221341B1 (en) |
| NO (1) | NO962714L (en) |
| NZ (1) | NZ278271A (en) |
| PL (1) | PL182298B1 (en) |
| RO (1) | RO117542B1 (en) |
| RU (1) | RU2153885C2 (en) |
| TJ (1) | TJ294B (en) |
| WO (1) | WO1995017908A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6461851B1 (en) | 1992-11-19 | 2002-10-08 | Anticancer, Inc. | High expression modules containing two or more tandem copies of a methioninase encoding sequence |
| US5891704A (en) * | 1992-11-19 | 1999-04-06 | Anticancer, Inc. | Method to produce high levels of methioninase |
| US6911309B2 (en) * | 1993-12-29 | 2005-06-28 | The Regents Of The University Of Californnia | Nucleic acids encoding MTAse |
| US6870037B1 (en) * | 1995-07-03 | 2005-03-22 | Arch Development Corporation | Methylthioadenosine phosphorylase compositions and methods of use in the diagnosis and treatment of proliferative disorders |
| JP3375834B2 (en) | 1995-10-30 | 2003-02-10 | 塩野義製薬株式会社 | Recombinant L-methionine γ-lyase |
| US5861154A (en) * | 1995-10-30 | 1999-01-19 | Shionogi & Co., Ltd. | Recombinant L-methionine γ-lyase |
| EP1316611B1 (en) * | 2000-09-05 | 2013-03-13 | AntiCancer, Inc. | L-methionine gamma-lyase with modified function |
| US20030129262A1 (en) * | 2001-08-30 | 2003-07-10 | Epner Daniel E. | Methionine restriction for cancer therapy |
| US20040127435A1 (en) * | 2002-08-02 | 2004-07-01 | Regents Of The University Of California | Uses for inhibitors of inosine monophosphate dehydrogenase |
| EP1594900A2 (en) | 2003-02-14 | 2005-11-16 | Salmedix, Inc. | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| US20110002978A1 (en) * | 2003-06-17 | 2011-01-06 | Harrison Roger G | Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof |
| RU2393866C2 (en) * | 2005-03-17 | 2010-07-10 | Проекто Де Биомедисина Сима, С.Л. | Application of 5'-methylthioadenosine (mta) for prevention and/or treatment of autoimmune diseases and/or graft rejection |
| EP2192905A4 (en) | 2007-08-29 | 2010-11-10 | Adam Lubin | Method for the selective therapy of disease |
| WO2009140007A2 (en) * | 2008-04-14 | 2009-11-19 | Ats Medical, Inc. | Tool for implantation of replacement heart valve |
| US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
| WO2020032951A1 (en) | 2018-08-09 | 2020-02-13 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
-
1993
- 1993-12-29 US US08/176,413 patent/US5571510A/en not_active Expired - Fee Related
-
1994
- 1994-12-22 PL PL94315229A patent/PL182298B1/en unknown
- 1994-12-22 DE DE69431167T patent/DE69431167T2/en not_active Expired - Fee Related
- 1994-12-22 RU RU96116159/14A patent/RU2153885C2/en not_active IP Right Cessation
- 1994-12-22 HU HU9601695A patent/HU221341B1/en not_active IP Right Cessation
- 1994-12-22 AT AT95906124T patent/ATE221785T1/en not_active IP Right Cessation
- 1994-12-22 RO RO96-01324A patent/RO117542B1/en unknown
- 1994-12-22 CZ CZ19961869A patent/CZ291281B6/en not_active IP Right Cessation
- 1994-12-22 EP EP95906124A patent/EP0805690B1/en not_active Expired - Lifetime
- 1994-12-22 WO PCT/US1994/014919 patent/WO1995017908A1/en not_active Ceased
- 1994-12-22 TJ TJ96000320A patent/TJ294B/en unknown
- 1994-12-22 NZ NZ278271A patent/NZ278271A/en unknown
- 1994-12-22 JP JP7518169A patent/JPH09507754A/en not_active Ceased
- 1994-12-22 AU AU14459/95A patent/AU694161B2/en not_active Ceased
- 1994-12-22 CA CA002180262A patent/CA2180262A1/en not_active Abandoned
- 1994-12-22 CN CN94195042A patent/CN1143325A/en active Pending
-
1996
- 1996-06-27 NO NO962714A patent/NO962714L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0805690A4 (en) | 1999-05-12 |
| HU9601695D0 (en) | 1996-08-28 |
| HU221341B1 (en) | 2002-09-28 |
| CN1143325A (en) | 1997-02-19 |
| NO962714D0 (en) | 1996-06-27 |
| ATE221785T1 (en) | 2002-08-15 |
| EP0805690B1 (en) | 2002-08-07 |
| NO962714L (en) | 1996-08-26 |
| AU694161B2 (en) | 1998-07-16 |
| CZ186996A3 (en) | 1996-12-11 |
| JPH09507754A (en) | 1997-08-12 |
| DE69431167D1 (en) | 2002-09-12 |
| CZ291281B6 (en) | 2003-01-15 |
| US5571510A (en) | 1996-11-05 |
| CA2180262A1 (en) | 1995-07-06 |
| HUT75070A (en) | 1997-04-28 |
| EP0805690A1 (en) | 1997-11-12 |
| NZ278271A (en) | 2001-07-27 |
| RU2153885C2 (en) | 2000-08-10 |
| AU1445995A (en) | 1995-07-17 |
| RO117542B1 (en) | 2002-04-30 |
| PL182298B1 (en) | 2001-12-31 |
| WO1995017908A1 (en) | 1995-07-06 |
| DE69431167T2 (en) | 2003-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9601695D0 (en) | Method for selective methionine starvation of malignant cells in mammals | |
| USD290604S (en) | Telephone set | |
| USD292374S (en) | Bottle | |
| USD292880S (en) | Bottle | |
| USD300743S (en) | Handset telephone with articulated end | |
| USD292095S (en) | Handset telephone | |
| USD282792S (en) | Portable desk | |
| USD296894S (en) | Telephone station set | |
| USD302820S (en) | Combined fuel pump and canopy structure for a service station | |
| MY103665A (en) | Anthracycline glycosides | |
| USD301687S (en) | Mine roof support plate | |
| USD293104S (en) | Desk telephone set | |
| USD292400S (en) | Headset telephone | |
| USD288319S (en) | Telephone station set | |
| IT1238615B (en) | PROCEDURE FOR THE ENRICHMENT OF POWDERS, RESULTING IN THE CUBILOT, WITH METALLIC PARTICLES | |
| USD275669S (en) | Telephone stand or similar keyboard article | |
| USD297146S (en) | Guitar body | |
| USD279781S (en) | Portable personal computer | |
| USD276383S (en) | Combined key holder and defensive weapon | |
| USD292094S (en) | Handset telephone | |
| MY132605A (en) | Separable bumper structural body | |
| USD314566S (en) | Document holder for computer keyboard | |
| USD302270S (en) | Keyboard | |
| USD295040S (en) | Telephone station set | |
| USD324845S (en) | Passenger ferry superstructure |